[The effect of erythropoietin therapy on biocompatibility in hemodialysis].
In order to evaluate the treatment with erythropoietin (EPO) on selected indicators of biocompatibility the authors examined 8 patients dialyzed for prolonged periods before treatment (HTK = 0.23, median), during EPO treatment (Recormon, administered by the s.c. route, HTK = 0.28) in the course of 4-hour haemodialysis on dialyzers with a Cuprophan membrane. The examination before and during treatment was made under equal conditions. Heparinization was also equal despite the fact that during EPO in four patients the residual blood volume in the dialyzer was increased. Comparison of the results before treatment and during EPO treatment did not reveal at any of the collection times (before dialysis, during the 15th, 10th, 60th and 235th minute of the procedure significant differences in the number of leucocytes, plasma concentrations of the C5a complement component, number of thrombocytes and activated coagulation times. Plasma concentrations of the thrombin-antithrombin III complex were in EPO during the 60th minute of haemodialysis significantly lower (p < 0.05) than before EPO. The authors conclude that EPO treatment does not have a significant effect on changes in the number of leucocytes in blood during haemodialysis nor on the activation of complement by an alternative way. EPO does not lead to a greater activation of the coagulation system during haemodialysis; the lower concentration of the thrombin-antithrombin III complex suggests the opposite. Explanation of this finding, similarly as detection of the cause of the increased residual blood volume in some patients, calls for further investigation.
Opatrný
K
K
Interní oddĕlení Strahov, Praha.
Opatrná
S
S
Vít
L
L
Opatrný
K
K
Vilimovskij
A
A
Sulková
S
S
Bláha
J
J
D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001672:Biocompatible Materials; D001772:Blood Cell Count; D015936:Complement C5a / Q000032:analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D006435:Renal Dialysis
D001672:Biocompatible Materials; C046193:antithrombin III-protease complex; D004921:Erythropoietin; D015936:Complement C5a; D000990:Antithrombin III; D010447:Peptide Hydrolases
Vliv lécby erytropoetinem na biokompatibilitu pri hemodialýze.